View Older Stories View More Recent Stories

May 22, 2023 11:01AM Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
May 11, 2023 01:41PM Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023
May 3, 2023 06:59AM Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
May 2, 2023 06:59AM Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference
May 1, 2023 07:06AM Bristol-Myers Squibb (BMY) Announces FDA Priority Review of BLA and EMA Validation of Reblozyl
May 1, 2023 07:05AM U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-
May 1, 2023 07:00AM Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
May 1, 2023 07:00AM Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
May 1, 2023 06:59AM Bristol-Myers Squibb's (BMY) TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi Meet Primary Endpoint of Overall Response Rate
May 1, 2023 06:59AM Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint
Apr 27, 2023 06:59AM Bristol Myers Squibb Reports First Quarter Financial Results for 2023
Apr 26, 2023 04:14PM Bristol-Myers Squibb (BMY) Announces Leadership Transition
Apr 26, 2023 04:14PM Bristol Myers Squibb Announces Leadership Transition Plan
Apr 26, 2023 02:44PM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval for CAMZYOS (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy
Apr 26, 2023 02:42PM Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
Apr 26, 2023 06:59AM Bristol-Myers Squibb (BMY) Announces New U.S. Manufacturing Facility for Viral Vector Production
Apr 26, 2023 06:59AM Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
Apr 20, 2023 05:15AM Bristol-Myers Squibb (BMY) and Tubulis Enter License Agreement to Develop Next Generation ADCs for the Treatment of Cancer Patients
Apr 20, 2023 05:00AM Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
Apr 17, 2023 07:09AM Bristol-Myers (BMY), 2seventy (TSVT) Announces Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed R/R Multiple Myeloma
Apr 17, 2023 06:59AM Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
Apr 11, 2023 07:04AM Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic Development
Mar 31, 2023 08:08AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
Mar 31, 2023 08:07AM Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
Mar 30, 2023 09:11AM Bristol-Myers Squibb (BMY) Announces Neoadjuvant Opdivo with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable NSCLC at Three Years in the CheckMate -816 Tria
Mar 30, 2023 09:10AM Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial
Mar 28, 2023 07:00AM Bristol-Myers Squibb (BMY) Receives European Commission Approval of Sotyktu, a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Mar 28, 2023 06:59AM Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Mar 28, 2023 05:20AM Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
Mar 15, 2023 06:59AM Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
Mar 9, 2023 06:59AM Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023
Mar 3, 2023 04:16PM Bristol Myers Squibb Announces Dividend
Mar 3, 2023 07:01AM Bristol-Myers Squibb (BMY) Granted EU Approval of Reblozyl for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
Mar 3, 2023 06:59AM Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
Mar 2, 2023 06:59AM The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
Feb 28, 2023 07:00AM Bristol-Myers Squibb (BMY) Announces FDA Accepts Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo
Feb 28, 2023 06:59AM U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….
Feb 28, 2023 06:59AM Bristol Myers Squibb to Participate in Cowen’s 43rd Annual Health Care Conference
Feb 27, 2023 06:59AM Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology
Feb 17, 2023 10:00AM Bristol-Myers Squibb (BMY) Reports Strong Adjuvant Opdivo Data from CheckMate -274 Trial
Feb 17, 2023 10:00AM Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckM
Feb 16, 2023 07:00AM Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation (AFib) and its Symptoms
Feb 13, 2023 05:02PM Exelixis (EXEL) and Bristol Myers Squibb (BMY) Reports Strong Results from Phase 3 CheckMate-9ER Trial
Feb 13, 2023 05:00PM Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Feb 10, 2023 11:15AM Bristol-Myers (BMY), 2seventy (TSVT) Announces Abecma Reduced Risk of Disease Progression, Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for R/R Multiple Myeloma Based on Results f
Feb 10, 2023 11:13AM Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Resul
Feb 3, 2023 06:59AM Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
Feb 2, 2023 06:59AM Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
Jan 27, 2023 07:06AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Reblozyl for Adult Patients with Anemia-Associated, NTD Beta Thalassemia
Jan 27, 2023 07:05AM Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia
View More Recent Stories View Older Stories